 | 6th Annual Pain Management Conference The future of analgesia
14th - 15th October 2009, BSG House, London
Background InfoKey Speakers
• Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford
• Kevin Lee, Vice President, Drug Discovery, GlaxoSmithKline
• Lars Arendt-Nielsen, Director, Pain Research Group, Centre for Sensory-Motor Interaction, Aalborg University
• Rolf Karlsten, Medical Science Director, AstraZeneca
• Roger Pertwee, Director of Pharmacology, GW Pharmaceuticals
• Stephen Wright, Research and Development Director, GW Pharmaceuticals
• Robert Pinnock, Director, Scientific Liaison, United Kingdom & Ireland, Merck, Sharp & Dohme
• Anastasia Liapi, Director, Business Development, Astellas
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Steve England, Associate Research Fellow, Pfizer
• Stephen Hammond, Chief Executive Officer, Scottish Biomedical
• Stephen Peroutka, Vice President, Neurosciences, PRA International
• William K. Schmidt, Vice President, Clinical Development, CrystalGenomics
• Nathaniel Katz, President & Chief Executive Officer, Analgesic Research
• Klaus Schaffler, Research Professor, University of Waterloo and President, Human Pharmacodynamic Research
• Luda Diatchenko, Chief Scientific Officer, Algynomics Pain costs approximately €200m in Europe1 and $1trillion in the developed world in treatments, loss of productivity and disability payments2. While therapeutic breakthroughs have been rare over the past 30 years, exciting advances are heralding much-needed and more effective analgesics2,3. Modern lifestyles and an aging population will lead the global pain market, currently worth $35bn, to increase by a forecast 65% to $55bn by 20233. With an estimated 100 billion tablets or 35,000 tons of aspirin consumed annually in the United States alone, pain management continues to be among the fastest growing sectors of the global pharmaceutical market. Yet pain-related conditions frequently lack effective therapy and there are few analgesic classes- all of which have safety issues. The attrition rate for new analgesics remains stubbornly high, and prospects for even the most effective animal-tested drug is 5%. The danger of addiction to opioids remains unresolved and patents are rapidly nearing their end. Chronic conditions such as spinal cord injury, neuralgias and phantom limb pain remain vast unmet needs, and the search for new analgesics continues unabated. Industry is responding to the challenge, with over 40 new products in the pipeline and new opportunities for reformulated compounds, as well as generics and biologicals. Insights from genomics, molecular biology, neuroimaging and human experimental models are driving targeted therapies, from receptor antagonists and ion channel modulators, to monoclonal antibodies and novel NSAIDs, many of which are now in clinical trials. By attending Visiongain’s 6th Annual Pain Management conference, you will acquire distilled, market-focussed intelligence from outstanding speakers in key areas including:
• Rational approaches to chronic pain management with opioids and new FDA risk evaluation and mitigation strategy guidelines
• Clinical results from human experimental pain models in early drug development
• Genetic architecture of human pain perception and the molecular mechanisms underlying various types of pains
• New insights from voltage-gated sodium and calcium channel targets
• Emerging strategies in exploiting cannabinoid receptors agonists and their clinical results
• Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era
• Adequate PoC for new mechanisms
• Biomarkers for pain– from model to clinic
• Neuroimaging tools for analgesic drug discovery
• Reducing the numbers of patients in human clinical trials by eliminating non-responders
• Novel treatments for peripheral neuropathies undergoing clinical trials
• Outcome studies for neuropathic pain treatments in clinical practice and their implications for drug development and study design
• Innovative methods for conducting proof-of-concept studies
• Monoclonal antibody therapies for osteoarthritis in Phase III clinical trials
• Laser technology as a novel technique in human pain research
• The future market landscape in chronic pain
• New insights into migraine pain and the molecular basis of effective therapeutics Who should attend?
Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, and Professors in:
• Analgesia
• Neuropharmacology
• CNS Clinical Discovery/Nervous System Research
• Neuroscience
• Neurology
• Arthritis
• Migraine
• Medicinal Chemistry
• Healthcare
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Antibody Research and Development
• Protein Technologies
• Pre-Clinical/Clinical R&D
• Disease Genetics
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Clinical Trials
• Business Development
• Licensing and External Research
• Global Marketing and Medicine Poster Presentation At a busy conference it is hard to make sure everyone who shares your interests knows what you are doing. Maximise your time at Visiongain’s Pain Management meeting by sharing your results in a poster presentation. With a plethora of key decision makers, take advantage of this senior networking opportunity.
Please send your 200 word abstract, in English, to info@visiongainglobal.com for approval. The deadline for submissions is Monday, October 5th, 2009. Please include contact details for the corresponding author(s).
Academic institutions will not be charged a fee if booked as full-price delegates. Posters submitted by pharmaceutical and biotechnology firms will be charged a fee of £199.
Posters submitted by service providers / vendors are welcome and will be subject to evaluation. Upon approval a fee of £500 will apply. You must be booked on as a full price delegate to present a poster.
Please note that all posters will be displayed at the discretion of Visiongain Ltd and are subject to approval. Due to limited space, please register your interest early.
1 Tracey, I. (2008). Prof. Irene Tracey on fMRI and pain. Downloaded from the World Wide Web on April 8th, 2009: http://wspain.blogspot.com/2008/10/prof-irene-tracey-on-fmri-and-pain.html.
2 Max, M.B. and Stewart, W.F. (2008). Molecular Epidemiology of Pain: A New Discipline for Drug Discovery. Nature Reviews Drug Discovery, 7 (8), pp. 647-658.
3 Visiongain, (2008). The Global Pain Market, 2008-2023. Day 1Day One, Wednesday 14th October 2009 09:20 Registration and refreshments 09:50 Opening address from the chair Chas Bountra
Chief Scientist, Structural Genomics Consortium
University of Oxford
Formerly Vice President & Head, Biology, GlaxoSmithKline 10:00 The chronic pain market: building a roadmap to commercial success
• The market dynamics in key chronic pain indications
• Positioning your product in the pain market: when R&D meets marketing
• The future market landscape in chronic pain: gazing into the crystal ball and not seeing black swans Anastasia Liapi
Director, Business Development
Astellas 10:40 Genetic architecture of human pain perception
• Pain perception is one of the most complex measurable traits and an aggregate of many intermediate phenotypes
• Genetic variation and environmental events mediate human pain phenotypes
• Separate vulnerability pathways underlie patient heterogeneity in chronic pain Luda Diatchenko
Chief Scientific Officer
Algynomics 11:20 Morning refreshments 11:40 Ion channel targets to discover analgesics
• Contribution/importance of different ion channels (IC) in pain
• Developing in vitro assays, stable cell lines over-expressing recombinant human IC and DRGs
• Current assay methodologies to discover novel analgesics Stephen Hammond
Chief Executive Officer
Scottish Biomedical 12:20 Voltage-gated sodium channels as targets for novel analgesics
• Importance of Navs in pain signalling
• Nav1.7; supporting evidence from human genetic studies
• Future prospects for finding subtype-selective compounds Steve England
Associate Research Fellow
Pfizer 13:00 Networking lunch 14:20 Analgesic effects of a potent and selective kinase inhibitor of neurotrophin receptors TrkA, TrkB and TrkC
• The Neurotrophin / Trk pathway is a clinically validated pain target
• Small molecular inhibitors of the Trk receptor kinases can be extremely potent and selective
• Such small molecule inhibitors show efficacy in pre-clinical models of pain, such as CFA thermal hyperalgesia and mechanical allodynia, fracture pain and inflammatory (CIA) pain Dr Jim Winkler
Vice President, Discovery and Translational Biology
Array BioPharma 15:00 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era
• What have we learned about GI and cardiovascular risk?
• What strategies are being employed to improve GI and cardiovascular safety?
- Example #1: Naproxcinod, a nitric-oxide donating analog of naproxen
- Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase
• Are regulatory hurdles manageable in the USA and Europe? William K. Schmidt
Vice President, Clinical Development
CrystalGenomics 15:40 Afternoon refreshments 16:00 Emerging strategies in exploiting cannabinoid receptors agonists
• A current strategy for targeting cannabinoid receptors
• Emerging strategies for targeting cannabinoid receptors
• Results from clinical trials Roger Pertwee
Director of Pharmacology
GW Pharmaceuticals Stephen Wright
Research and Development Director
GW Pharmaceuticals 16:40 Pain management in the 21st century: where are we and what are the prospects for the future?
Topics will include: the brain’s role in pain, new targets for the future, and peripheral mechanisms in analgesia and side-effect management. Pharmacovigilance and the role of pricing and reimbursement will also be discussed. If you would like to submit a question to the panel, please email: john.shah@visiongainglobal.com. Chair: Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford, Formerly Vice President & Head, Biology, GlaxoSmithKline
Panellists: Kevin Lee, Vice President, Drug Discovery, GlaxoSmithKline
Anastasia Liapi, Director, Business Development, Astellas
William K. Schmidt, Vice President, Clinical Development, CrystalGenomics
Nathaniel Katz, President, Analgesic Research 17:20 Closing remarks from the chair 17:30 Networking Drinks Reception
Take your discussions further and build new relationships in a relaxed and informal setting
Day 2Day Two, Thursday 15th October 2009 09:20 Registration and refreshments 09:50 Opening address from the Chair Chas Bountra
Chief Scientist, Structural Genomics Consortium
University of Oxford
Formerly Vice President & Head, Biology, GlaxoSmithKline 10:00 Migraine pain: what have we learned to date?
• To review previous and current theories of the origin of migraine pain
• To assess the clinical relevance of the various hypotheses
• To suggest an unifying mechanism to explain migraine pain as well as the molecular basis of effective therapeutics Stephen Peroutka
Vice President, Neurosciences
PRA International 10:40 Development of treatments for peripheral neuropathies
• Existing treatment options
• Preclinical research
• Growth factors
• POC modeling in humans Theo F. Meert
Professor, Katholieke Universiteit Leuven and University of Antwerp
Senior Research Fellow, Neuroscience, Johnson & Johnson 11:20 Morning refreshments 11:40 Outcome of treatment in neuropathic pain in clinical practice - its implication for drug development and study design Rolf Karlsten
Medical Science Director
AstraZeneca 12:20 Chronic pain management with opioids: a rational approach
• Foundations of opioid risk management
• Abuse-deterrent formulations: are they a pipe dream?
• New FDA guidelines for risk evaluation and mitigation strategies 13:00 Networking lunch 14:00 A new potent opioid with fast return to normal GI transit
• Neo1509 is an original opioid which exhibits a full return to normal GI transit during analgesia
• Long duration of action (10 to 12 hours bolus, iv and po), as potent as morphine, no addiction in place preference assays
• Currently in regulatory preclinical development Roger Lahana
Chief Executive Officer
Neorphys 14:20 Human experimental pain models in early drug development
• Translation from animal to human pain models
• Back-translation from human models to animal models
• Translating from human experimental pain models in volunteers to pain patients
• Mechanisms based proof-of-concept studies
• The concept of multi-model, multi-tissue pain models
• Integrating pain models in phase Ib studies Lars Arendt-Nielsen
Director, Pain Research Group, Centre for Sensory-Motor Interaction
Aalborg University 15:00 Developing imaging tools for analgesic drug discovery
• Overview of tools available and what they measure
• Examples relating to sensitivity and mechanism of action
• Discussion of where they “sit” in the drug discovery process Karolina Wartolowska
Clinical Research Fellow, Oxford FMRIB Centre
University of Oxford 15:40 Afternoon refreshments 16:00 Innovative methods for conducting proof-of-concept studies
• Tools to reduce sample sizes by:
- Identifying accurate pain reporters
- Measuring pain more precisely
- Measuring physical activity objectively Nathaniel Katz
Director, Program on Opioid Risk Management, Tufts University School of Medicine and President & Chief Executive Officer
Analgesic Research 16:40 Laser technology as a novel technique in pain research
• Principles of laser technology in pain research
• Skin types/models to work with laser stimulation
• Validity and reproducibility of laser stimuli - ending in a database on analgesics Klaus Schaffler
Research Professor, University of Waterloo
President, Human Pharmacodynamic Research 17:20 Alternative approaches to proof-of-concept studies
Panellists will discuss issues raised in the four preceding talks concerning the development of human experimental trials for novel analgesics. If you would like to submit a question to any of the participants, please email: john.shah@visiongainglobal.com Panellists: Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford, Formerly Vice President & Head, Biology, GlaxoSmithKline
Lars Arendt-Nielsen, Director, Pain Research Group, Centre for Sensory-Motor Interaction, Aalborg University
Nathaniel Katz, President, Analgesic Research
Klaus Schaffler, Research Professor, University of Waterloo and President, Human Pharmacodynamic Research
Robert Pinnock, Director, Scientific Liaison, United Kingdom & Ireland, Merck, Sharp & Dohme
Karolina Wartolowska, Clinical Research Fellow, Oxford FMRIB Centre, University of Oxford
17:50 Chair’s closing remarks and end of conference PartnersPlatinum Sponsor: IMS Health
Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries. With $2.2 billion in 2007 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide.
View Brochure
PricesPrices
|
|
|
|
